Sort   by:  
 Page size 
ProteomicsTriple SILAC glycoproteomic analysis of NSCLC cell lines
Protein glycosylation plays a fundamental role in a multitude of biological processes, and the associated aberrant expression of glycoproteins in cancer has made them attractive targets as biomarkers and therapeutic targets. In this study, we examined differentially expressed glycoproteins in cell l...
ORGANISM(S): Homo Sapiens (ncbitaxon:9606) 
2016-03-10 | MSV000079569 | MassIVE
GenomicsRB Loss in Resistant EGFR Mutant Lung Adenocarcinomas that Transform to Small Cell Lung Cancer
Tyrosine kinase inhibitors (TKIs) are effective treatments for non-small cell lung cancers (NSCLCs) with epidermal growth factor receptor (EGFR) mutations. However, they do not lead to cures, and, on average, relapse occurs typically occurs afterafter an average of one year of continuous treatment....
EGAS00001001102 | EGA
ProteomicsComparative proteome analysis across non-small cell lung cancer cell lines
Non-small cell lung cancer (NSCLC) cell lines are widely used model systems to study molecular aspects of lung cancer. Comparative and in-depth proteome expression data across many NSCLC cell lines has not been generated yet, but would be of utility for the investigation of candidate targets and mar...
ORGANISM(S): Homo sapiens (Human) 
2015-09-14 | PXD002556 | Pride
Pca Non-small cell lung cancer K-ras Silac Proteome profiling Egfr 
GenomicsTranscriptomic heterogeneity of EGFR-mutant non-small cell lung cancer evolution towards small cell lung cancer
Transcriptomic heterogeneity of EGFR-mutant non-small cell lung cancer evolution towards small cell lung cancer
PRJNA1081397 | ENA
TranscriptomicsMiR-21 is an EGFR-regulated anti-apoptotic factor in lung cancer from never-smokers
Approximately 15% of lung cancer cases are not associated with smoking and show molecular and clinical characteristics distinct from those in smokers. Epidermal growth factor receptor (EGFR) gene mutations, which are correlated with sensitivity to EGFR-tyrosine kinase inhibitors (EGFR-TKIs), are mo...
ORGANISM(S): Homo sapiens 
2010-05-15 | E-GEOD-14936 | biostudies-arrayexpress
GenomicsTargeting FGFR overcomes EMT-mediated resistance in EGFR mutant non-small cell lung cancer
Targeting FGFR overcomes EMT-mediated resistance in EGFR mutant non-small cell lung cancer
PRJNA472050 | ENA
ProteomicsTKI-resistant T790M EGFR Mutation Rewired EGFR Translocation Routes through Switching Interactome in Non-Small Cell Lung Cancer
Epidermal growth factor receptor (EGFR) harboring active mutations, Del19 and L858R, are most common oncogenic mutations in in non-small cell lung cancer (NSCLC) patients. The preferred treatment at first line is tyrosine kinase inhibitor (TKI) administration while the TKI-resistance usually develop...
ORGANISM(S): Homo Sapiens (human) 
2023-05-31 | PXD034228 | JPOST Repository
GenomicsPlasma cell-free DNA hydroxymethylomes define disease state in EGFR-mutant non-small cell lung cancer
Plasma cell-free DNA hydroxymethylomes define disease state in EGFR-mutant non-small cell lung cancer
PRJNA963056 | ENA
GenomicsFusion genes in EGFR mutant lung cancer
Fusion genes in EGFR mutant lung cancer
PRJNA755752 | ENA
OtherTranscriptomic heterogeneity of EGFR-mutant non-small cell lung cancer evolution towards small cell lung cancer
Histological transformation from epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) to small cell lung cancer (SCLC) is the major resistance mechanism of EGFR tyrosine kinase inhibitors (TKIs). In our analysis of 59 regions of interest from EGFR-mutant NSCLC or combine...
ORGANISM(S): Homo sapiens 
2024-07-30 | GSE259387 | GEO
Sort   by:  
 Page size